Cargando…

Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients

BACKGROUND: Apatinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been used to treat esophagogastric adenocarcinoma. However, the dosage of apatinib varies greatly in clinical practice, and its safety in esophageal squamous cell carcinoma (ESCC) patients is unclear. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Zhang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798775/ https://www.ncbi.nlm.nih.gov/pubmed/35116396 http://dx.doi.org/10.21037/tcr-20-2492

Ejemplares similares

Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma
por: Yang, Ying, et al.
Publicado: (2017)

Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma
por: Yang, Ying, et al.
Publicado: (2020)

Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report
por: Guo, Longhua, et al.
Publicado: (2021)

Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma
por: Liu, Yun, et al.
Publicado: (2021)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Tracheoesophageal fistula closure after staged dose-escalated radiotherapy for esophageal squamous cell carcinoma: a case report
por: Zhen, Chan-jun, et al.
Publicado: (2023)

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
por: Zhen, Hongchao, et al.
Publicado: (2020)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report
por: Liang, Li-Jun, et al.
Publicado: (2018)

Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study
por: Tanaka, Yoshihiro, et al.
Publicado: (2010)

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study
por: Zhang, Xiaodong, et al.
Publicado: (2019)

Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer
por: Li, Jing, et al.
Publicado: (2019)

Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy
por: Sun, Zhiwei, et al.
Publicado: (2019)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Integrated bioinformatics analysis to identify key genes related to the prognosis of esophageal squamous cell carcinoma
por: Yang, Ying, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
por: Yang, Bo, et al.
Publicado: (2022)

Phase I dose-escalation trial of S-1 combined with carbon-ion radiotherapy for sinonasal squamous cell carcinoma
por: Takahashi, Daiki, et al.
Publicado: (2020)

Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
por: Dai, Xichao, et al.
Publicado: (2023)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
por: Chiang, Nai-Jung, et al.
Publicado: (2016)

Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
por: Tanaka, Toshihiro, et al.
Publicado: (2019)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Dose-escalation of radiation may improve outcomes of squamous cell carcinoma of bladder
por: Karmakar, Shreyasee, et al.
Publicado: (2019)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)
por: Zhang, Wencheng, et al.
Publicado: (2020)

A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study
por: Wang, Lei, et al.
Publicado: (2017)

Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2019)

A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma
por: Vlacich, Gregory, et al.
Publicado: (2021)

Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2010)

Reply to: Dose-escalation of radiation may improve outcomes of squamous cell carcinoma of bladder
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial
por: Barone, C, et al.
Publicado: (2007)

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
por: Chi, Dongmei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lirgs0mo0k88vqqod1kb12h2g6